Atlas Trials

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

Clinical trial NCT02720523 · COMPLETED

Trial details

NCT number
NCT02720523
Sponsor
AbbVie
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Rheumatoid Arthritis
Start date
2016-03-22
Primary completion
2017-08-03
Enrollment
197

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.